Second, will the CML-specific T cells not be anergized in vivo, such that even if the presentation of BCR-ABL peptides does occur, the T cells will not be able to mount a productive anti-leukemic response? This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.